Experienced in Myeloproliferative Neoplasms (MPN)

Markus G. Manz

Zurich, ZH, CH 
Experienced in Myeloproliferative Neoplasms (MPN)
Zurich, ZH, CH 
OverviewLocationsClinical Research

Overview

Markus Manz practices in Zurich, Switzerland. Mr. Manz is rated as an Experienced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Langerhans Cell Histiocytosis, Myeloperoxidase Deficiency, and Bone Marrow Transplant.

His clinical research consists of co-authoring 236 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Myeloproliferative Neoplasms (MPN).

Gender
Male

Locations

Zurich, ZH, Switzerland
Other Locations
Bern, BE, Switzerland
Bellinzona, TI, Switzerland
Basel, BS 4056, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Pomalidomide, Dexamethasone
Study Phase: Phase 2
View 1 Less Clinical Trial

236 Total Publications

Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
Journal: Nature medicine
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Manz's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile